Core 2: Biocontainment and Immune Monitoring Core

核心2：生物遏制和免疫监测 摘要 这一计划的总体目标是开发一种或多种疫苗，这些疫苗将在下一次 贝塔冠状病毒暴发。为了支持这一总体目标，一个生物遏制和免疫监测核心 一直集中在杜克大学。核心由通过公爵提供的技术和服务组成 区域生物内容物实验室(Duke RBL)、Duke人类疫苗研究所(DHVI)流式细胞术 和细胞分选设施，以及蒙特菲奥里和法拉利抗体鉴定实验室。RBL公爵 是美国国立卫生研究院建造的12个RBL之一，并于2007年第一个开始运行。公爵RBL提供了一个 安全、可靠和合规的BSL2-3/ABSL2-3和特定药剂研究活动的管理保护伞 在杜克大学。杜克RBL拥有最先进的BSL3生物遏制实验室模块，高 遏制细胞分类，一系列服务单位(即微生物学、病毒学、免疫学和动物学 模型支持)，一个集成的ABSL3间隔层，以支持小动物挑战模型，并是目的 旨在支持新出现/再次出现的感染的诊断、治疗和疫苗的开发 和生物防御。核心将例行公事地为项目调查人员提供高遏制细胞分类和 综合表型、多重生物标志物分析、病毒载量、中和和抗体依赖 细胞毒性试验和小动物SARS-CoV-2攻击模型。对所有五个核心至关重要 目标/任务是对仪器和分析的持续质量控制的承诺；以及坚定的承诺 预测并满足所有四个项目和国家核电计划核心的需求。通过在教育和工作中 与项目调查人员合作，我们将优化分析，以满足他们的需求，并更有效地 利用BioContent提供的最先进的仪器和生物遏制设施 和免疫监测核心。由一个团队进行全面和集中的免疫监控，该团队拥有经过验证的 跟踪记录将为所有拟议的研究增加价值，并将使项目调查人员能够更好地、更多地 高效地设计和开发潘贝塔冠状病毒疫苗。

Core 2: Biocontainment and Immune Monitoring Abstract The overall goal of this program is to develop a vaccine or vaccines that will be available when the next betaCoV outbreak occurs. In support of this overall goal, a Biocontainment and Immune Monitoring Core has been centralized at Duke. The Core is comprised of technologies and services offered through the Duke Regional Biocontanment Laboratory (Duke RBL), the Duke Human Vaccine Institute (DHVI) Flow Cytometry and Cell Sorting facility, and the Montefiori and Ferrari antibody characterization laboratories. The Duke RBL is one of 12 NIH-constructed RBLs, and was the first to begin operation in 2007. The Duke RBL provides an administrative umbrella for safe, secure and compliant BSL2-3/ABSL2-3 and Select Agent research activities at Duke University. The Duke RBL has state-of-the-art BSL3 biocontainment laboratory modules, high- containment cell sorting, a portfolio of service units (i. e. Microbiology, Virology, Immunology and Animal Models Support), an integrated ABSL3 vivarium to support small animal challenge models, and was purpose built to support the development of diagnostics, therapeutics and vaccines for emerging/reemerging infections and biodefense. The Core will routinely provide program investigators with high-containment cell sorting and comprehensive phenotyping, multiplex biomarker profiling, viral load, neutralization and antibody-dependent cellular cytotoxicity assays, and small animal SARS-CoV-2 challenge models. Critical to all five Core Aims/Tasks is a commitment to ongoing quality control of instruments and assays; and a strong commitment to anticipate and meet the needs of all four projects and the NHP Core. By educating and working in collaboration with program investigators we will optimize assays to meet their needs and more effectively utilize the state-of-the-art instrumentation and biocontainment facilities available through the Biocontaniment and Immune Monitoring Core. Comprehensive and centralized immune monitoring by a team with a proven track-record will add value to all proposed studies, and will allow project investigators to better, and more efficiently, design and develop panbetaCoV vaccines.